TY - JOUR
T1 - Nebido
T2 - A long-acting injectable testosterone for the treatment of male hypogonadism
AU - Harle, Lindsey
AU - Basaria, Shehzad
AU - Dobs, Adrian S.
PY - 2005/8/1
Y1 - 2005/8/1
N2 - Over the last six decades, tremendous strides have been made in the development of safe, efficacious and 'patient-friendly' modalities of testosterone replacement therapy in men. The most recent forms of androgen replacement that are in widespread use include testosterone patch and gel. These preparations are convenient in their use and deliver a physiological amount of testosterone. Although these transdermal preparations are gaining popularity, many hypogonadal men still receive treatment with intramuscular esters. Testosterone enanthate remains the most commonly prescribed ester. Although testosterone esters are efficacious in terms of improving bone and muscle mass, they possess unfavourable pharmacokinetics that result in fluctuations in the mood, energy and sexual function of patients. Furthermore, these esters need to be injected every 2 - 4 weeks. Hence, there has been a need to develop long-acting esters that can be administered infrequently and deliver a physiological amount of testosterone without major fluctuations. Recently, injectable testosterone undecanoate (Nebido®) has become available in Europe and will soon be marketed in south America, Asia and Australia. In this paper, the structure, pharmacokinetics, efficacy and side-effect profile of testosterone undecanoate will be reviewed and also compared with other existing testosterone esters.
AB - Over the last six decades, tremendous strides have been made in the development of safe, efficacious and 'patient-friendly' modalities of testosterone replacement therapy in men. The most recent forms of androgen replacement that are in widespread use include testosterone patch and gel. These preparations are convenient in their use and deliver a physiological amount of testosterone. Although these transdermal preparations are gaining popularity, many hypogonadal men still receive treatment with intramuscular esters. Testosterone enanthate remains the most commonly prescribed ester. Although testosterone esters are efficacious in terms of improving bone and muscle mass, they possess unfavourable pharmacokinetics that result in fluctuations in the mood, energy and sexual function of patients. Furthermore, these esters need to be injected every 2 - 4 weeks. Hence, there has been a need to develop long-acting esters that can be administered infrequently and deliver a physiological amount of testosterone without major fluctuations. Recently, injectable testosterone undecanoate (Nebido®) has become available in Europe and will soon be marketed in south America, Asia and Australia. In this paper, the structure, pharmacokinetics, efficacy and side-effect profile of testosterone undecanoate will be reviewed and also compared with other existing testosterone esters.
KW - Male hypogonadism
KW - Testosterone enanthate
KW - Testosterone undecanoate
UR - http://www.scopus.com/inward/record.url?scp=23844468548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23844468548&partnerID=8YFLogxK
U2 - 10.1517/14656566.6.10.1751
DO - 10.1517/14656566.6.10.1751
M3 - Review article
C2 - 16086661
AN - SCOPUS:23844468548
SN - 1465-6566
VL - 6
SP - 1751
EP - 1759
JO - Expert opinion on pharmacotherapy
JF - Expert opinion on pharmacotherapy
IS - 10
ER -